- Revenue Growth: Total revenue increased 19% YoY ($1.9B growth), with recurring revenue up 27% and product sales from EPKINLY and Tivdak contributing 31% of growth.
- Operating Profit Surge: Operating profit jumped 56% to $1.1B, with net profit reaching $531M in H1 2025.
- Product Sales Momentum: EPKINLY sales soared 74% to $211M YoY, while Tivdak sales grew 60% overall, driven by launches in Japan, Europe, and pending Germany entry.
- Pipeline Advancements: Epcoritamab showed 79% reduced risk of progression/death in follicular lymphoma; Rina-S achieved 50% confirmed response rate in endometrial cancer and plans for three Phase III trials by end-2025.
- Strong Cash Position: Ended H1 2025 with $3B in cash, supporting pipeline expansion and updated 2025 revenue guidance to $3.5–3.7B.
Commercial Performance and Pipeline Progress
EPKINLY and Tivdak sales grew 60% year-over-year, with EPKINLY sales up 74% to $211 million. The company has made progress in launching Tivdak in Japan and Europe and expects to launch it in Germany soon. In terms of pipeline progress, epcoritamab has shown promising results in follicular lymphoma, with a 79% reduction in the risk of disease progression or death. Rina-S has also shown positive results in endometrial cancer, with a 50% confirmed overall response rate.
Guidance and Outlook
Genmab improved its 2025 financial guidance, expecting revenue to be in the range of $3.5 billion to $3.7 billion, with operating profit between $1.1 billion and $1.4 billion. The company is confident in its leading sales position globally and is encouraged by the feedback from physicians and customers. According to Tahamtan Ahmadi, "We are prioritizing our resources on the most promising opportunities and are excited about the potential for epcoritamab and Rina-S."
Valuation Metrics
With a P/E Ratio of 13.12, P/B Ratio of 16.63, and P/S Ratio of 3.81, Genmab's valuation appears reasonable considering its strong financial performance and pipeline progress. The company's ROIC of 107.52% and ROE of 25.61% also suggest that it is generating strong returns on its investments.
Analysts' Estimates and EPS
Analysts estimate next year's revenue growth at 15.8%. The company's actual EPS came out at $34.41, relative to estimates at $28.36, indicating a strong beat. With a strong cash position and promising pipeline, Genmab appears well-positioned for long-term value creation.